Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2004

View Archived Issues

In vivo characterization of a rapid-acting thyroid hormone derivative

Chemokine microbicide formulation effective against HIV-1 in macaques

Influenza vaccine from Aventis now available for shipping

Dual neuroprotection from oxygen and nitrogen reactive species

PEP-005 shows high selectivity against leukemia

New phase I study of AT-1001 for Fabry's disease

Phase I studies begin for ABT-894 for neuropathic pain

OrthoLogic completes acquisition of Chrysalis BioTechnology

New indication approved for Hyzaar

European recommendation for extended dosing of Aranesp

GlycoGenesys enters agreements to close on funding from institutions

Yakult Honsha and Taiho to copromote oxaliplatin in Japan

Portola licenses Millennium's Factor Xa inhibitor program

Five series of chemokine CCR5 antagonists presented by GSK

AstraZeneca presents novel GSK-3 inhibitors for AD and other uses

Japanese researchers prepare and test a new antineoplastic antibiotic

New KDR and FGFR inhibitors with potential in solid tumor therapy

New epothilone derivatives in early development at Novartis

New glucagon antagonists discovered by Novo Nordisk scientists

Novel PAI-1 inhibitors produced by the microorganism Stachybotris atra

Human multidrug resistance protein 1 targeted in malignant cells

Frovatriptan provides relief for menstrual associated migraine

Merck & Co. and DOV enter agreement for triple uptake inhibitor development

NPS to promote Amgen's Kineret to rheumatologists

Approvable letter for ZyLET

Sinovac's phase I SARS study progresses

Dosing begins in phase I study of the thrombin inhibitor ARC-183

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...